Transdermal estroprogestins versus transdermal estrogen plus oral dihydrogesterone replacement in menopause

Journal of Endocrinological Investigation

Volumn 19, Issue 5, 1996, Pages 268-272

  Marchesoni, D ^a   Dal Pozzo, M ^a   Dal Magro, L ^a   Paternoster, D M ^a   Ferroni, E ^a   Maggino, T ^a   Romagnolo, C ^a   Mozzanega, B ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Dihydrogesterone; Hormonal replacement therapy; Menopause; Transdermal estroprogestins

Indexed keywords

20ALPHA DIHYDROPROGESTERONE; DRUG DERIVATIVE; ESTRADIOL; LIPID; LIPOPROTEIN; NORETHISTERONE; NORETHISTERONE ACETATE;

ARTICLE; BLOOD; BLOOD CLOTTING; BLOOD PRESSURE; BODY MASS; BONE; BONE DENSITY; ESTROGEN THERAPY; FEMALE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MENOPAUSE; METABOLISM; METHODOLOGY; MIDDLE AGED;

20-ALPHA-DIHYDROPROGESTERONE; ADMINISTRATION, CUTANEOUS; BLOOD COAGULATION; BLOOD PRESSURE; BODY MASS INDEX; BONE AND BONES; BONE DENSITY; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LIPIDS; LIPOPROTEINS; MENOPAUSE; MIDDLE AGED; NORETHINDRONE;

EID: 0030134551     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347862     Document Type: Article

References (34)

1. Henderson B.E., Ross R.K., Lobo R.A., Pike M.C., Mack T.M. Re-evaluating the role of progestogen therapy after menopause. Fertil. Steril. 49: 9S, 1988.
2. Paganini-Hill A., Ross R.H., Henderson B.E. Postmenopausal oestrogen treatment and hearth stroke: a prospective study. Br. Med. J. 297: 519, 1988.
3. Egeland G.M., Kuller L.H., Matthews K.A., Kelsey S.F., Cauley J., Guzick D. Hormone replacement therapy and lipoprotein changes during early menopause. Obstet. Gynecol. 76: 776, 1990.
4. Sullivan J.M., Van Der Zwaag R., Lemp G.F., Hughes J.P., Moddok V., Kroetz F.W., Ramanthan K.B., Mirvis D.M. Estrogen replacement therapy and coronary artery disease: effect on survival in postmenopausal women. Arch. Intern. Med. 150: 2557, 1990.
5. Sitruk-Ware R., Ibarra De Palcios P. Oestrogen replacement therapy and cardiovascular disease in postmenopausal women. Maturitas 11: 259, 1989.
6. Judd H.L., Meldrum D.R., Deftos L.J., Henderson B.E. Estrogen replacement therapy: indications and complications. Ann. Intern. Med. 98: 195, 1983.
7. Drapier- Faure E. Reflexions sur le traitment hormonal de la menopause en 1990. Gynecologie 41: 273, 1990.
8. Gambrell R.D. Jr. The prevention of endometrial cancer in postmenopausal women with progestogens. Maturitas 1: 107, 1978
9. Whitehead M., Townsend P.T., Pryse-Davies J., Ryder T.A., King R.J.B. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N. Engl. J. Med. 305: 1599, 1981.
10. Huovinen K., Autio S., Kaprio J. Peroral lynestrenol and arterial disease in mentally retarded women. Acta Obstet. Gynecol. Scand. 67: 211, 1988.
11. Ottosson U.B., Johansson B.G., von Shoultz B. Subfractions of high density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogen and natural progesterone. Am. J. Obstet. Gynecol. 151: 746, 1985.
12. Da Cleyn K., Buytaert P., Delbeke L., Gerris J. Equine estrogen-dydrogesterone therapy in the management of postmenopausal women. Eur. J. Obstet. Gynecol. Reprod. Biol. 23: 201, 1986.
13. Hargrove J.T., Maxson W.S., Colston Wentz A., Burnett L.S. Menopausal hormone replacement therapy with continuos daily oral micronized estradiol and progesterone. Obstet. Gynecol. 73: 606, 1989.
14. L'Hermite M. Risk of estrogens and progestogens. Maturitas 12: 215, 1990.
15. Jensen J., Riis B.J., Christiansen K. Long term effects of percutaneous estrogen and oral progesterone on serum lipoprotein in postmenopausal women. Am. J. Obstet. Gynecol. 156: 166, 1987.
16. Hirvonen E., Malkonen M., Manninen V. Effects of different progestogens on lipoprotein during postmenopausal replacement therapy. N. Engl. J. Med. 304: 560, 1981.
17. Williams S.R., Frenchek B., Speroff T., Speroff L. A study of combined continous ethinyestradiol and norethindroneacetate for postmenopausal hormone replacement. Am. J. Obstet. Gynecol. 162: 438, 1990.
18. Horowitz M., Wishart J.M., Need A., Morris H.A., Nordin C. Effects of norethisterone on bone related biochemical variables and forearm bone mineral in postmenopausal osteoporosis. Clin. Endocrinol. (Oxf.) 193: 649, 1993.
19. Abdall H.I., McKay Hart D., Lindsay R., Leggate I., Hooke A. Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet. Gynecol. 66: 789, 1985.
20. De Aloysio D., Mauloni M., Bottiglioni F. Il climaterio femminile. Monduzzi Ed., Bologna, 1988, p. 363.
21. Bengtsson C., Lindquist O. Menopausal effects on risk factors for ischemic heart disease. Maturitas 1: 165, 1978.
22. Ginsburg J., Swinhoe J., O'Reilly B. Cardiovascular responses during the menopausal hot flush. Br. J. Obstet. Gynecol. 88: 925, 1981.
23. Prough S.G., Aksel S., Weibe R.H., Shepherd J. Continuos estrogen/progestin therapy in menopause. Am. J. Obstet. Gynecol. 157: 1449, 1987.
24. Hemminki E., Tofo P., Malin M., Kangas I. Physicians views on hormone therapy around and after menopause. Maturitas 16: 163, 1993.
25. Marchesoni D., Baggio G., Pigozzo S., Mozzanega B. Variazioni indotte nel metabolismo dei lipidi da un trattamento sequenziale con estrogeni e progestinico in menopausa. In: Zichella L., Perrone G. (Eds.), Terza età della donna - Prevenzione e terapia in climaterio. Monduzzi Ed., Bologna, 1989, p. 487.
26. Mozzanega B., Marchesoni D., Lazzaro A.R., Simioni P., Girolami A. Complesso protrombinico e fattore VIII nella menopausa recente: effetti del medrossiprogesterone acetato in monoterapia ed in associazione sequenziale con gli estrogeni. In: Bottiglioni F., De Aloysio D. (Eds.) Il climaterio femminile: esperienze italiane di un decennio. Monduzzi Ed., Bologna, 1988 p. 557.
27. Whitehead M.I., Fraser D., Schenkel L., Crook D., Stevenson J.C. Transdermal administration of oestrogen/progestogen hormone replacement therapy. Lancet 335: 310, 1990.
28. Notelovitz M., Kitchens C.S., Ware M.D., Hirschberg K., Coone L. Combination estrogen and progestogen replacement therapy does not adversely affect coagulation. Obstet. Gynecol. 62: 596, 1983.
29. Haffner S.M., Valdez R.A. Endogenous sex hormones: impact on lipids, lipoprotein, and insulin. Am. J. Med. 98 (Suppl. A): 40S, 1995.
30. Soma M.R., Osnago-Gadda I., Paoletti R., Fumagalli R., Morrisett J.D., Meschia M., Crosignani P.G. The lowering of lipoprotein (a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch. Intern. Med. 153: 1462, 1993.
31. The writing group from the PEPI trial. Effect of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 273: 199, 1995.
32. Psaty B.M., Heckbert S.H. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch. Intern. Med. 154: 1333, 1994.
33. Nabulsi A.A., Folsom A.R. Association of hormone-replacement therapy with cardiovascular risk factors in postmenopausal women. N. Engl. J. Med. 328: 1069, 1993.
34. Stampfer M.J., Colditz G.A., Willet W.C. Postmenopausal estrogen therapy and cardiovascular disease. N. Engl. J. Med. 325: 756, 1991.